Table 3 Number of cycles of treatment administered at recommended Phase II dose (dose level 2, n=20 patients)

From: A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

Number of cycles administered

n

%

1

13

65

2

5

25

3

1

5

4

—

—

5

—

—

6

1

5

Back to article page